Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726992 | 0.88 | POLA1 (0.72) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6724476 | 0.86 | POLA1 (0.68) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6735590 | 0.82 | POLA1 (0.61) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6697784 | 0.82 | KCNH2 (0.59) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6730407 | 0.81 | POLA1 (0.63) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6729967 | 0.81 | KCNH2 (0.58) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6729395 | 0.80 | KCNH2 (0.60) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6729589 | 0.80 | KCNH2 (0.62) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6729519 | 0.79 | KCNH2 (0.58) | POLA1KCNH2ALDH1A1F2MEN1 | |
| SCHEMBL6709492 | 0.79 | KCNH2 (0.61) | POLA1KCNH2ALDH1A1F2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ANDERSON DAVID JOHN (US) | 2004-02-12 | — | — | US | claimed |
| US-6624159-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-09-23 | — | — | US | claimed |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | claimed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ANDERSON DAVID JOHN (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624159-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885KCNH2 919/4885ALDH1A1 779/4885 |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | POLA1 2447/4885KCNH2 4095/4885ALDH1A1 1190/4885 |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885KCNH2 919/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.